|Publication number||US20050033202 A1|
|Application number||US 10/822,437|
|Publication date||Feb 10, 2005|
|Filing date||Apr 12, 2004|
|Priority date||Jun 29, 2001|
|Also published as||US7981062, US20100121231, WO2005110326A2, WO2005110326A3|
|Publication number||10822437, 822437, US 2005/0033202 A1, US 2005/033202 A1, US 20050033202 A1, US 20050033202A1, US 2005033202 A1, US 2005033202A1, US-A1-20050033202, US-A1-2005033202, US2005/0033202A1, US2005/033202A1, US20050033202 A1, US20050033202A1, US2005033202 A1, US2005033202A1|
|Inventors||Alan Chow, George McLean, Vincent Chow, Jay Cech, Christopher Bonner, Vladimir Gelfandbein|
|Original Assignee||Chow Alan Y., Mclean George Y., Chow Vincent Y., Jay Cech, Bonner Christopher M., Vladimir Gelfandbein|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (99), Referenced by (12), Classifications (15), Legal Events (3)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation-in-part of non-provisional application Ser. No. 10/186,295, filed Jun. 28, 2002, which is a continuation-in-part of non-provisional application Ser. No. 10/056,793, filed Jan. 23, 2002, which claims the benefit of provisional application Ser. No. 60/301,877, filed Jun. 29, 2001, which prior applications are hereby incorporated by reference in their entirety.
The present invention is directed generally to improving biological cell function and more specifically to improving retinal cell visual function in damaged and/or degenerated retinas and also to protecting retinal cells from degeneration.
Certain biological chemical compounds such as nerve growth factors (NGF), neurotrophins, brain-derived neurotrophic factors (BDNF), fibroblastic growth factor (FGF), glial cell line-derived neurotrophic factors (GDNF), and numerous other similar biological chemical compounds, all collectively known as survival-type factors can slow down the process of cellular degeneration in a number of biological degenerative diseases, specifically in retinal degenerative diseases and also promote cellular growth in other situations.
In studies, the application of survival-type factors was found to promote and maintain certain retinal cellular functions. For example, brain-derived neurotrophic factor (BDNF), neurotrophin-4 (NT-4), neurotrophin-5 (NT-5), fibroblastic growth factor (FGF) and glial cell line-derived neurotrophic factor (GDNF) have been shown to enhanced neurite outgrowth of retinal ganglion cells and to increase their survival in cell culture. GDNF has been shown to preserve rod photoreceptors in the rd/rd mouse, an animal model of retinal degeneration. Nerve growth factor (NGF) injected into the intra-ocular area of the C3H mouse, also a model of retinal degeneration, results in a significant increase of surviving photoreceptor cells compared to controls (Bosco and Linden, 1999; Caleo et al., 1999; Carmignoto et al., 1989; Cui et al., 1998; Frasson et al., 1999; Lambiase and Aloe, 1996; Reh et al., 1996).
However, while many prostheses are known that attempt to restore vision by using photoactive properties of semiconductors designed to provide sufficient electrical stimulation of retinal cells to induce a perceptual response, few devices or treatments are available that can slow, stop or reverse retinal degeneration.
The present invention provides mechanically activated objects or devices for use in treating degenerative retinal diseases. In particular, devices in accordance with the present invention provide stimulus/irritation to tissues of an eye through active mechanical forces to effectuate treatment of a degenerative retinal disease. It is hypothesized that such mechanical forces, when applied to tissues of the eye, stimulate the production of beneficial materials such as survival-type factors, particularly neurotrophic growth factors, in response to the irritation or trauma of the eye tissues.
In one embodiment, devices in accordance with the present invention are configured for chronic implantation (thereby applying chronic stimulation/irritation) in or on an eye. More particularly, such devices may be configured for contact with a retina of the eye, preferably positioned in a subretinal space. Various embodiments of the present invention comprise a moving member configured for chronic contact with at least a portion of the eye, which moving member is activated by an actuator. In some embodiments, the actuator may be distally located relative to the moving member. Alternatively, the moving member may be supported by a body member that, optionally, also supports the actuator. Regardless, when activated by the actuator, the moving member stimulates or irritates the eye by causing displacement of at least a portion of the eye to thereby effectuate treatment.
Many human retinal diseases cause vision loss by partial to complete destruction of the vascular layers of the eye that include the choroid and choriocapillaris, both of which nourish the outer anatomical retina and a portion of the inner anatomical retina of the eye. A number of other retinal diseases cause vision loss due to partial to complete degeneration of one or both of the two anatomical retinal layers directly, due to inherent abnormalities of these layers. The components of the retinal layers include Bruch's membrane and retinal pigment epithelium which comprise the “outer anatomical retinal layer”, and the photoreceptor, outer nuclear, outer plexiform, inner nuclear, inner plexiform, amacrine cell, ganglion cell and nerve fiber layers which comprise the “inner anatomical retinal layer”, also known as the “neuroretina”. The outer portion of the neuroretina is comprised of the photoreceptor and bipolar cell layers and is also known as the “outer retina” which is to be distinguished from the “outer anatomical retinal layer” as defined above.
Loss of function of the outer retina is commonly the result of dysfunction of the outer anatomical retinal layer that provides nourishment to the outer retina and/or to direct defects of the outer retina itself. The final common result, however, is dysfunction of the outer retina that contains the light sensing cells, the photoreceptors. Some of these “outer retina” diseases include age-related macula degeneration, retinitis pigmentosa, choroidal disease, long-term retinal detachment, diabetic retinopathies, Stargardt's disease, choroideremia, Best's disease, and rupture of the choroid. The inner portion of the neuroretina, however, often remains functionally and anatomically quite intact and may be activated by the appropriate stimuli.
Although prosthetic electrical devices designed to replace damaged or missing retinal cells have been used to treat vision loss caused by outer retinal degeneration, physical stimulation to improve large areas of retinal cell visual function is novel. As a non-limiting explanation, the promotion of improved retinal cell visual function by physical stimulation may be explained by the stimulation of production and release of growth factors (GFs); more specifically, neurotrophic-type growth factors (NTGFs), by the stimulated retinas in response to the wounding or trauma inflicted by the physical stimulation. The synthesis and/or secretion of neurotrophic factors would then improve retinal cell function and survival in conditions where these activities would be lost.
Animal and human studies have been used to show that electrical stimulation may be used to improve the general inherent visual function of damaged retinal cells in direct contact with and surrounding an implanted electrical artificial silicon retina prosthesis (Chow et al., 2002). The mechanism of action may be related to the upregulation and production of endogenous survival-type factors by the retina due to an electrical effect on cellular membranes which may include a direct irritant effect of the electric current.
An irritant effect is also produced by the physical effect that includes a mechanical foreign-body effect, of an implant placed into or in contact with the retina. Such an irritant effect is akin to a mild damage effect on the retina which is known to upregulate the production of survival-type factors. For example, an incision into the retina, called a retinotomy, is known to upregulate, albeit temporarily, certain survival-type factors that also temporarily slow down retina degeneration in a rat model of retinal degeneration (Peng et al., 1997). A non-electrical foreign body that is inert or almost inert is therefore capable of producing a chronic irritant effect that chronically upregulates endogenous survival factors in the retina and to produce a long-term slowdown or prevention of a retinal degenerative process.
A system and method are disclosed of placing a non-electrical physical and/or mechanical foreign body into or in contact with the retina to irritate and therefore chronically stimulate the upregulation of survival-type factors to slow down and/or prevent retinal degeneration. The subject matter of this application also includes the devices used to produce the said chronic irritation of the retina. Such non-electrical chronic irritant devices theoretically may have the ability to slow down the degeneration in other organ systems such as the central nervous system.
The present invention discloses both devices and novel methods to non-electrically irritate and/or stimulate the retina by physical and/or mechanical stimulation/irritation to improve large areas of retinal visual function and to protect the retina from degeneration.
A subject (patient) may be a human being or a non-human animal, but is preferably a human. Usually the individual has suffered some type of retinal damage and/or degeneration that results in some degree of visual loss and/or has a condition that will result in retinal damage and/or degeneration. A healthy subject does not have a condition that will result in retinal damage and/or degeneration and/or has not suffered retinal damage and/or degeneration.
Improving Visual Function
Improving visual function refers to improving a targeted function of the eye, selected by the artisan, and includes improving any to all of the following capabilities of the eye, retina and visual system: perception of brightness in the presence of light, perception of darkness in the absence of light, perceptions of contrast, color, shape, resolution, movement and visual field size.
Primary visual degradation means loss of visual function due to malfunction of, damaged to, or degeneration of structures found in the eye. Secondary visual degradation means loss of visual function due to secondary damage, typically from lack of use of the vision-associated portions of the brain. Improving visual function means to improve the visual function of primary visual degradation, secondary visual degradation or both.
The eye (or eyeball) has the usual definition in the art. Eye includes all interior and exterior surfaces, components, contents and cavities of the eye. The eye does not include the eyelid.
The retina of the eye can be divided into sectors as is commonly accepted in the art. Such sectors are described by the use of the terms temporal, nasal, superior, inferior, by clock hour designation, and by the number of degrees away from the macula. For example, the temporal sector of the retina is the retina temporal to a perpendicular plane cutting through retina from the 12 o'clock to the 6 o'clock positions and through the macula. In another example, the superior sector is the retina superior to a perpendicular plane cutting through the 9 o'clock to 3 o'clock positions and through the macula. In a further example, the superior-temporal sector is the intersection of these two sectors, a pie-shaped area delineated from the 9 o'clock position of the peripheral retina to the macula and then clockwise to the 12 o'clock position. More specific locations of the retina can be designated by degrees away from the macula and clock hour location: for example, 20 degrees away from the macula at the 3 o'clock (nasal) position. The number of degrees away from the macula is in visual axes degrees. These axes all intersect through the lens of the eye.
The visual field sectors correspond oppositely to the retinal sectors as is commonly understood in the art. For example, the superior-temporal sector of the retina corresponds to the inferior-nasal portion of the visual field.
To be peripheral to an object, device or other landmark includes all surrounding parts, but not the object, device or landmark, i.e., the object, device or landmark, together with the peripheral portion, constitutes the whole.
Light refers not only to the electromagnetic spectrum that humans can readily perceive visually (approximately 400 nm to 750 nm), but also includes ultraviolet light (<400 nm in wavelength) as well as infrared light (>750 nm in wavelength).
The invention can be used to improve visual function in subjects in which the retina is damaged by disease, degeneration, condition, or trauma and/or to slow down or stop the progression of damage by disease, degeneration, condition or trauma. Common diseases, conditions, degeneration or trauma that are particularly amenable to this treatment include age-related macula degeneration, retinitis pigmentosa, Leber's congenital amaurosis, Stargardt's disease, Best's disease, diabetic retinopathy, long-term retinal detachment, and choroidal damage.
Referring to the drawings,
The layers of the eye at the posterior pole from inside to outside are shown in
Devices and Methods to Provide Physical Stimulation
Any object that can provide a chronic or prolonged physical stimulation or irritation to the eye can be used as a source of physical stimulation. These devices may include, but are not limited to, electrically inert objects, mechanically or electrically activated objects, and chemical or biological agents.
The physical stimulation may be provided by any object that can remain in physical contact with and/or irritate cells, such as retinal cells of an eye, for an extended period of time. The extended period of time may be years, such as would be the case with a device that would be implanted in the eye and persist indefinitely in the eye unless it was purposefully extracted. Alternatively, the extended period of time may be a limited time, for example one year, after which the implanted device or agent would biodegrade or otherwise be absorbed.
In one preferred embodiment, the source of physical stimulation is at least one device or object that is electrically inactive such that it is neither photoactive, a source of electrical stimulation, nor in electrical communication with a source of electrical stimulation. The device may be constructed from silicon, metal, plastic, ceramic, glass, wood, sand or any of a number of materials. For example, an object of any shape or depth may be used. These shapes may include, but not be limited to, to geometric shapes, such as straight lines, circles, squares, rectangles, and triangles as well as three-dimensional shapes, such as balls, cubes, cylinders, or cones.
In yet other embodiments, the device may be an interconnected array of implantable elements. For example,
Other means to provide physical stimulation includes implanting devices that deliver an irritant. For example, oils, detergents, bile salts, etc. may be applied in small quantities that are yet sufficient to physically stimulate the cells. Preferably, the irritant is packaged, such as in a capsule, so that the irritant is slowly released over time, and so that the “packaging” is ultimately absorbed by the body. Examples of biodegradable substances include biodegradable polymers. Biodegradable polymers decompose when placed inside an organism and thus eliminate the need to remove the implant after the bioactive agent has been released, since the polymer will gradually break down and may be metabolized or excreted from the body. The decomposition of a biodegradable polymer can be observed as a decline in the molecular weight of the polymer over time. Polymer molecular weights can be determined by a variety of methods including size exclusion chromatography (SEC), and are generally expressed as weight averages or number averages. A polymer is biodegradable if, when in phosphate buffered saline (PBS) of pH 7.4 and a temperature of 37° C., its weight-average molecular weight is reduced by at least 25% over a period of 6 months as measured by SEC.
Polymers which could be useful as “packaging” capsules include, but are not limited to, polyesters, such as poly(caprolactone), poly(glycolic acid), poly(lactic acid), poly(hydroxybutryate); copolymers of caprolactone, glycolic acid, lactic acid, and hydroxybutryate; polyanhydrides, such as poly(adipic anhydride); poly(para-dioxanone); poly(malic acid); polyamines; polyurethanes; polyesteramides; polyorthoesters; polyacetals; polyketals; polycarbonates; polyorthocarbonates; polyphosphazenes; poly(amino acids); chitin; chitosan; and copolymers and mixtures thereof.
Chemical or biological agents, including growth factors, can also be introduced into the eye to provide a prolonged stimulation to enhance rescue and retina functional improvement. This additional step is attractive because some factors, especially neurotrophic-type growth factors, may improve retinal function and provide limited neuronal rescue in eyes with retinal degeneration and dysfunction. These growth factors include, but are not limited to, glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), brain derived neurotrophic growth factor (BDNGF), neurotropin-3 (NT-3), neurotropin-4 (NT-4), neurotropin-5 (NT-5), ciliary neurotropic factor (CNTF) and fibroblastic growth factor (FGF). These growth factors can be delivered to the eye by coating the device with growth factor(s) before implantation, by injection of the growth factor(s) into the locations of the subretinal space, vitreous cavity, subconjunctival space, subscleral space, and/or the anterior chamber either singly or in combination with each other, as a single dose or as multiple repeat doses before, during and/or after implantation of the device(s).
Location of Stimuli
The chronic physical stimulation provided by at least one device may be provided subretinally, epiretinally, subsclerally (between the sclera and choroid; also referred to as suprachoroidally), subchoroidally (between the choroid and Bruch's membrane), on the scleral surface, on or under the conjuctival surface and/or from or within any structure of the eye. Other means of providing physical simulation to the retina and eye may include devices that deliver chronic stimulation from the underside of the eyelid(s). Preferably, physical stimulation is from the subretinal space which is an area that is in close proximity to the damaged retinal cells.
Therefore, in one embodiment, the chronically irritating/stimulating agent can be inserted in a way that it is placed in direct contact with the damaged retinal cells. In another embodiment, the chronically irritating/stimulating agent can be placed adjacent to, but not in direct contact with, the damaged retinal cells. In response to the prolonged trauma inflicted by the irritant, healthy retinal cells may be chronically stimulated to produce and release growth factors, such as neurotrophic growth factors, to help enhance retinal cell function.
Implantation Sites and Surgical Methods
In one embodiment, the physical stimulation is preferably in the subretinal space in the periphery and/or mid-periphery of the eye, outside of the macula. For devices that are implanted, more than one device may be implanted, if needed, in an eye to stimulate a larger area of the retina, and multiple devices can be implanted in paracentral locations such as one in each of the four paracentral quadrants, approximately, but not limited to, 5 to 80 degrees peripheral to the macula. In other embodiments, one or more devices may be implanted in the macular region of the eye. In one embodiment the implants may be placed in the subretinal space in the mid-periphery approximately 20 degrees away from the macula, using one device or up to approximately four devices evenly spaced on a perimeter in the midperiphery. Cells to stimulate include the remaining cells of the inner retina.
In yet another embodiment, an implantable device is designed to be implanted onto the epiretinal surface (i.e. on the nerve fiber layer side) of the retina. It is retained in position by retinal tacks, biocompatible glues, or other means. In the case of electrical implantable devices, subconjunctival/scleral placement of the device results in less efficient electrical stimulation of the retina compared to a subretinally or epiretinally placed device, but the extraocular location of the device decreases the surgical risk to a patient since intraocular surgery would not be required for its implantation. The subconjunctival/scleral placement of a device also allows a stable device position to be achieved without fixating devices or glues (i.e., the device is held in place between the conjunctiva and sclera).
Surgical methods are well known in the art (Peyman et al., 2000). Descriptions of specific surgeries for implantation of electrical stimulation devices, which are also applicable to other physical stimulating devices, have been extensively described (Chow, U.S. Pat. No. 5,024,223, 1991; Chow and Chow, U.S. Pat. No. 5,397,350, 1995; Chow and Chow, U.S. Pat. No. 5,556,423, 1996; Chow and Chow, 1997; Chow et al., 2001; Chow and Peachey, 1999; Chow and Chow, U.S. Pat. No. 5,895,415, 1999; Chow and Chow, U.S. Pat. No. 6,230,057 B1, 2001).
In another embodiment, electrically inert objects, chemical, and/or biological agents can be inserted into an eye in several ways. Chemical and biological agents, such as growth factors, can be delivered to the eye by coating a substrate with these factor(s) before implantation and/or by injecting these factor(s) into the locations of the subretinal space, vitreous cavity, subconjunctival space, subscleral/suprachoroidal space, subchoroidal space and/or the anterior chamber either singly or in combination with each other, as a single dose or as multiple repeat doses independent of, before, during and/or after implantation of the coated substrate or other electrical stimulating device. Electrically inert object(s) can be delivered to the eye by placing it directly into the subretinal space, vitreous cavity, subconjunctival space, subscleral space, and/or the anterior chamber through implantation or injection performed as previously described for the retinal implantable devices.
Further embodiments in accordance with the present invention, particularly mechanically activated embodiments, are further illustrated in
A first schema of mechanically activated embodiments is illustrated in
A first exemplary device 208 in accordance with the schema of
In this embodiment, an actuator 212 comprises at least one projecting arm coupled to (e.g., integrally formed with) the moving member 210. The actuator 212 may be fabricated from the same or different materials as the moving member 210, with the additional design constraint that the actuator 212 is intended to directly contact the fluid material in the vitreous cavity. Although a single actuator 212 is illustrated in
As mentioned above, the actuator 212 is intended to contact the fluid material (e.g., comprising the vitreous or a replacement material) within the vitreous cavity directly. The vitreous comprises a clear, gel-like, relatively viscous material and, as a result, presents an inertial differential at the surface of the retina. Note that a replacement material within the vitreous cavity such as saline or aqueous, although less viscous, would still impart an inertial differential at the retinal surface. That is, as the eye moves by rotating within the orbit, differences in movement of the fluid material within the vitreous cavity relative to the surface of the retina are induced. As illustrated in
Referring now to
The moving member 222 is positioned over a cavity 226 formed within the body member 221. Within the cavity, one or more electrodes 230 are formed. Although not shown in
The voltage source 234, although represented in the abstract in
Referring now to
For example, in one embodiment, a fluid (preferably having a relatively low boiling point and exhibiting good biocompatibility) is placed in (and, preferably, completely fills) the cavity 244. Additionally, a heating element is also placed within the cavity while retaining a hermetic seal around the cavity. The heating element is further coupled to the voltage source 252. Collectively, the voltage source 252, heating element, cavity 244 and fluid function as the actuator. When power is applied to the heating element, the resulting heat causes the fluid to expand, leading to a pressure increase within the cavity 244. The increase in pressure causes the membrane 250 to deflect (illustrated in dashed lines) and thereby impinge upon adjacent ocular tissues. When heat is removed, the fluid cools and condenses, pressure decreases within the cavity, and the membrane returns to its relaxed state.
In another embodiment, the cavity 244 is provided with one or more bleed or flow orifices (for example, formed in the floor of the cavity 244) such that, after implantation of the device 240, tissue fluids slowly ingress into the cavity 244. At least two electrodes are fabricated into the cavity floor and connected to the voltage source 252. In this instance, the voltage source 252, electrodes, cavity 244 and tissue fluids collectively function as the actuator. When a voltage is applied at the electrodes, electrolysis creates gas bubbles at the electrodes. The size of the gas bubbles is proportional to the applied power. Regardless, the increased volume of the gas bubbles within the cavity 244 causes the membrane 250 to deflect. Thereafter, at the end of each stimulation cycle, the cavity is allowed to slowly equilibrate, via the flow orifices, with the tissue fluids and membrane 250 returns to its original position.
In yet another embodiment, the actuator 248 may comprise a fulcrum and lever arrangement, disposed within the cavity 244, in which one end of the lever is coupled to a shape-altering material. For example, so-called electro-active polymers (EAPs) or “artificial muscles” which alter their shape in response to an applied voltage may be employed for this purpose. U.S. Pat. No. 6,511,508 and U.S. Patent Application No. 20030139808 describe the use of a variety of EAP as well as other artificial muscle materials that may be used in conjunction with the present invention, the teachings of which are incorporated herein by this reference. In this case, one end of a length of EAP is affixed within the cavity 244 while the other end of the length of EAP is coupled to one end of the lever. Additionally, the EAP is coupled to the voltage source 252. Collectively, the fulcrum, lever, EAP and voltage source 252 function as the actuator in this instance. As known in the art, when a voltage is applied to a properly configured EAP, movement can be induced in the EAP. Using well-known mechanical principals, such movement by the EAP causes the lever to rotate about the fulcrum. In turn, the rotation of the lever causes the membrane 250 to deflect, thereby displacing adjacent ocular tissues. When the EAP is thereafter allowed to relax or is otherwise returned to its original state, the lever and membrane 250 return to their original positions.
In addition to the embodiments described in
A second schema of mechanically activated embodiments is illustrated in
In the second schema, unlike the first, the actuator 304 is extraocular (which is not necessarily exclusive of being implanted within the body, e.g., intraorbitally) but nevertheless acts upon the moving member 302. Examples of actuators suitable for this purpose include oscillators that induce mechanical waves in the ocular tissues and magnetic fields that penetrate the ocular tissues. Further examples include actuators that are mechanically and/or electrically coupled through an appropriate linkage to the moving member, which linkage penetrates the intervening ocular tissues.
In accordance with such a system, the moving member 312 can be designed to have a specific natural frequency. Being implanted, the moving member 312 is preferably fabricated from and/or coated with suitably biocompatible/biodurable materials. The actuator 314, in this case a mechanical oscillator, generates mechanical waves 316 (substantially at the natural frequency of the moving member, optimally) that propagate through the ocular media and impinge upon the moving member 312. Depending on how close the impinging waves 316 are to the natural frequency of the moving member 312, and taking into account the damping effects of the surrounding tissues, vibrations of controlled (but variable) magnitudes are imparted by the moving member 312 upon the surrounding ocular tissues (e.g., the retina) thereby stimulating/irritating the tissues. Techniques for generating mechanical waves, and hence for implementing an actuator 314 capable of generating such mechanical waves, are well known in the art and need not be described in further detail here. In practice, such an oscillator can be mechanically coupled directly to a surface of the eyeball through an appropriate (e.g., fluid) interface, or indirectly through tissues or structures adjacent the eyeball (e.g., through the eyelids or bones of the orbit). Although an external actuator 314 is depicted in
In another embodiment of the schema of
The present invention provides mechanically activated objects or devices for use in treating degenerative retinal diseases. In keeping with the hypothesis that mechanical stimulation or irritation of various tissues of the eye may give rise to upregulation of endogenous beneficial survival-type factors, the present invention teaches various mechanically activated approaches for eliciting such stimulus. In this manner, it may be possible to treat degenerative retinal diseases for which there were no previous treatments or cure.
Although particular embodiments have been disclosed herein in detail, this has been done for purposes of illustration only and is not intended to be limiting with respect to the scope of the appended claims that follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. Other aspects, advantages, and modifications are considered to be within the scope of the following claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US793004 *||Jul 23, 1904||Jun 20, 1905||Frank Howard May||Eye-massage machine.|
|US1684860 *||Mar 12, 1927||Sep 18, 1928||Catlin De Forest B||Eye-treating apparatus|
|US2525381 *||Sep 25, 1947||Oct 10, 1950||Tower Paul||Contact-type electrode holder|
|US2721316 *||Jun 9, 1953||Oct 18, 1955||Shaw Joseph D||Method and means for aiding the blind|
|US2760483 *||Oct 20, 1954||Aug 28, 1956||Tassicker Graham Edward||Retinal stimulator|
|US3320947 *||Oct 22, 1964||May 23, 1967||Knoll Max Hans||Device for the excitation of nerve networks|
|US3594823 *||Feb 11, 1969||Jul 27, 1971||Patent Management Inc||Visual substitution system with receptor scanning means|
|US3699970 *||Jun 23, 1970||Oct 24, 1972||Nat Res Dev||Striate cortex stimulator|
|US3766311 *||Apr 26, 1972||Oct 16, 1973||H Boll||Sensory substitution system|
|US3769961 *||Jul 20, 1972||Nov 6, 1973||I Fatt||Conjunctival device|
|US3848608 *||Jul 23, 1973||Nov 19, 1974||Gen Electric||Subject integument spatial stimulator|
|US3893444 *||Jan 17, 1974||Jul 8, 1975||Univ California||Non-invasively measuring arterial oxygen tension|
|US3914800 *||Jun 6, 1974||Oct 28, 1975||Inst Of Medical Sciences||Fluid mechanical tactile oscilloscope to augment the five senses|
|US4001867 *||Sep 23, 1975||Jan 4, 1977||Dionics, Inc.||Semiconductive devices with integrated circuit switches|
|US4018218 *||Mar 12, 1975||Apr 19, 1977||Carlson James E||Method and apparatus for sleep induction|
|US4089329 *||Mar 18, 1976||May 16, 1978||University Of Utah Research Institute||Noninvasive, continuous intraocular pressure monitor|
|US4211474 *||Jan 24, 1978||Jul 8, 1980||Compagnie Generale D'electricite||Ultra-rapid electro-optical shutter|
|US4251887 *||Apr 2, 1979||Feb 24, 1981||Anis Aziz Y||Posterior chamber capsular lens implant and method for implantation of the lens|
|US4271841 *||Jan 31, 1980||Jun 9, 1981||Medtronic, Inc.||Electro-ocular stimulation system|
|US4272910 *||Jul 10, 1980||Jun 16, 1981||Danz W R||Ocular prosthetic or the like|
|US4326529 *||Dec 5, 1979||Apr 27, 1982||The United States Of America As Represented By The United States Department Of Energy||Corneal-shaping electrode|
|US4484922 *||Jun 25, 1981||Nov 27, 1984||Rosenwald Peter L||Occular device|
|US4525776 *||Jun 2, 1980||Jun 25, 1985||Bell Telephone Laboratories, Incorporated||Arithmetic logic unit arranged for manipulating bits|
|US4551149 *||Feb 16, 1982||Nov 5, 1985||Michael Sciarra||Prosthetic vision system|
|US4600004 *||Sep 8, 1982||Jul 15, 1986||Osvaldo Lopez||Intraocular lens holder and inserter|
|US4601545 *||May 16, 1984||Jul 22, 1986||Kern Seymour P||Variable power lens system|
|US4603697 *||Jan 7, 1985||Aug 5, 1986||William Kamerling||System for preventing or treating open angle glaucoma and presbyopia|
|US4614193 *||Jun 7, 1984||Sep 30, 1986||Pain Suppression Labs, Inc.||Electronic glaucoma treatment apparatus and methodology|
|US4664117 *||Oct 9, 1984||May 12, 1987||Beck Stephen C||Apparatus and method for generating phosphenes|
|US4667676 *||Jun 17, 1985||May 26, 1987||Audimax, Inc.||Method of evaluating the vestibular system|
|US4679572 *||Mar 11, 1986||Jul 14, 1987||Intermedics, Inc.||Low threshold cardiac pacing electrodes|
|US4750498 *||Feb 21, 1986||Jun 14, 1988||Coopervision, Inc.||Method and tool for inserting an intraocular lens|
|US4810050 *||May 21, 1986||Mar 7, 1989||British Telecommunications Public Limited Company||Optical inverter and logic devices using same with buffer limited electrical interface|
|US4832202 *||May 19, 1987||May 23, 1989||General Foods Limited||Containers|
|US4873448 *||Apr 27, 1987||Oct 10, 1989||Omron Tateisi Electronics Co.||Input circuit having a photo-coupler with bi-directional indicator|
|US4874237 *||May 5, 1988||Oct 17, 1989||Lions Eye Inst. Of Western Australia||Electroretinogram apparatus|
|US4955378 *||Jan 17, 1989||Sep 11, 1990||University Of South Florida||Apparatus and methods for performing electrofusion at specific anatomical sites|
|US4989605 *||Mar 31, 1989||Feb 5, 1991||Joel Rossen||Transcutaneous electrical nerve stimulation (TENS) device|
|US5016633 *||Aug 8, 1989||May 21, 1991||Chow Alan Y||Artificial retina device|
|US5024223 *||Jul 6, 1990||Jun 18, 1991||Chow Alan Y||Artificial retina device|
|US5025811 *||Feb 16, 1990||Jun 25, 1991||Dobrogowski Michael J||Method for focal destruction of eye tissue by electroablation|
|US5099829 *||Apr 25, 1990||Mar 31, 1992||Wu An Chuan||Massage device good for eyes|
|US5109844 *||Oct 11, 1990||May 5, 1992||Duke University||Retinal microstimulation|
|US5109846 *||Nov 5, 1990||May 5, 1992||Physiodynamics, Inc.||Apparatus and method for electrotherapeutic treatment of structures associated with the eye|
|US5130528 *||Mar 1, 1991||Jul 14, 1992||International Business Machines Corporation||Opto-photo-electric switch|
|US5130776 *||Feb 22, 1990||Jul 14, 1992||Landis & Gyr Betriebs Ag||Ultraviolet-light photodiode|
|US5147284 *||Aug 9, 1990||Sep 15, 1992||Fedorov Svjatoslav N||Device and method for restoration of visual functions|
|US5154174 *||Apr 16, 1991||Oct 13, 1992||Marko Hawlina||Electrode for electroretinography and method of use|
|US5159927 *||Apr 5, 1991||Nov 3, 1992||Ferdinand Schmid||Visual prosthesis apparatus and method|
|US5223728 *||Apr 2, 1992||Jun 29, 1993||Motorola, Inc.||Optical switch integrated circuit|
|US5256882 *||Sep 17, 1992||Oct 26, 1993||Kabushiki Kaisha Toshiba||Signal transmission circuit having a latch-up function|
|US5338991 *||Dec 28, 1992||Aug 16, 1994||Lu Chao Cheng||High power solid state relay with input presence and polarity indication|
|US5341798 *||Dec 2, 1992||Aug 30, 1994||Grounauer Pierre Alain||Retractor device for human or animal tissue|
|US5351309 *||Jun 30, 1992||Sep 27, 1994||National Science Council||Image edge sensor|
|US5360438 *||Jan 26, 1993||Nov 1, 1994||Fisher Mary R||Method and device for improving cranial nerve function to improve muscle function and thereby overcome visual/perceptual dysfunction|
|US5397350 *||May 3, 1993||Mar 14, 1995||Chow; Alan Y.||Independent photoelectric artificial retina device and method of using same|
|US5411540 *||Jun 3, 1993||May 2, 1995||Massachusetts Institute Of Technology||Method and apparatus for preferential neuron stimulation|
|US5441040 *||Feb 2, 1994||Aug 15, 1995||Williams, Jr.; Barney K.||RDS speculum|
|US5491349 *||Apr 22, 1994||Feb 13, 1996||Kabushiki Kaisha Toshiba||Multi-color light emitting device|
|US5496355 *||Nov 21, 1994||Mar 5, 1996||Lipsky; Stephen N.||Extraocular muscle sensor and stimulator|
|US5522864 *||Oct 25, 1994||Jun 4, 1996||Wallace; Larry B.||Apparatus and method for ocular treatment|
|US5556423 *||Apr 20, 1994||Sep 17, 1996||Alan Y. Chow||Independent photoelectric artificial retina device and method of using same|
|US5578040 *||Jun 14, 1994||Nov 26, 1996||Smith; Albert C.||Ocular repair system and apparatus|
|US5618261 *||Oct 27, 1994||Apr 8, 1997||Nevyas; Herbert J.||Eye proptosing speculum and method|
|US5648655 *||Dec 26, 1995||Jul 15, 1997||Lsi Logic Corporation||Sensing device for capturing a light image|
|US5674263 *||Mar 18, 1996||Oct 7, 1997||Yamamoto; Hiroshi||Optic nerve image output device and method|
|US5717201 *||Apr 18, 1996||Feb 10, 1998||National Science Council||Double four-quadrant angle-position detector|
|US5782894 *||Mar 5, 1997||Jul 21, 1998||Israel; Ben||Device and method for improving ocular focusing at near vision points|
|US5837995 *||Nov 25, 1996||Nov 17, 1998||Alan Y. Chow||Wavelength-controllable voltage-phase photodiode optoelectronic switch ("opsistor")|
|US5865839 *||May 19, 1997||Feb 2, 1999||Doorish; John F.||Artificial retina|
|US5895414 *||Apr 10, 1997||Apr 20, 1999||Sanchez-Zambrano; Sergio||Pacemaker housing|
|US5895415 *||Jun 6, 1995||Apr 20, 1999||Optobionics Corporation||Multi-phasic microphotodiode retinal implant and adaptive imaging retinal stimulation system|
|US5935155 *||Mar 13, 1998||Aug 10, 1999||John Hopkins University, School Of Medicine||Visual prosthesis and method of using same|
|US5944747 *||Mar 13, 1998||Aug 31, 1999||Johns Hopkins University||Method for preferential outer retinal stimulation|
|US6032062 *||Aug 1, 1996||Feb 29, 2000||Nmi Naturwissenschaftliches Und Medizinisches Institut||Microelectrode arrangement|
|US6035236 *||Jul 13, 1998||Mar 7, 2000||Bionergy Therapeutics, Inc.||Methods and apparatus for electrical microcurrent stimulation therapy|
|US6066675 *||Sep 8, 1997||May 23, 2000||The Regents Of The University Of California||Method for treatment of retinal diseases|
|US6083251 *||Nov 12, 1998||Jul 4, 2000||Shindo; Kohei||Eye treatment method and apparatus|
|US6101411 *||Sep 24, 1998||Aug 8, 2000||Newsome; David A.||Dilation enhancer|
|US6154671 *||Jan 4, 1999||Nov 28, 2000||Optisinvest||Device for the intraocular transfer of active products by iontophoresis|
|US6230057 *||Mar 26, 1998||May 8, 2001||Optobionics Corporation||Multi-phasic microphotodiode retinal implant and adaptive imaging retinal stimulation system|
|US6264971 *||Nov 4, 1999||Jul 24, 2001||Btg International Limited||Ocular insert|
|US6275735 *||Jul 7, 1999||Aug 14, 2001||Bionergy Therapeutics, Inc.||Methods and apparatus for electrical microcurrent stimulation therapy|
|US6282449 *||Mar 4, 1999||Aug 28, 2001||William Kamerling||Method and device for causing the eye to focus on a near object|
|US6298270 *||Apr 23, 1999||Oct 2, 2001||Eberhard-Karls-Universitat Tubingen Universitatsklinkum||Retina implant|
|US6347250 *||Apr 23, 1999||Feb 12, 2002||Nmi Univ Tuebingen||Optically controllable microelectrode array for stimulating cells within a tissue|
|US6389317 *||Mar 31, 2000||May 14, 2002||Optobionics Corporation||Multi-phasic microphotodetector retinal implant with variable voltage and current capability|
|US6393327 *||Aug 9, 2000||May 21, 2002||The United States Of America As Represented By The Secretary Of The Navy||Microelectronic stimulator array|
|US6423001 *||Apr 6, 2001||Jul 23, 2002||Marcio Marc Abreu||Method and apparatus for signal transmission and detection using a contact device|
|US6427087 *||May 4, 2000||Jul 30, 2002||Optobionics Corporation||Artificial retina device with stimulating and ground return electrodes disposed on opposite sides of the neuroretina and method of attachment|
|US6458157 *||Jul 29, 1998||Oct 1, 2002||Suaning Gregg Joergen||Retinal stimulator|
|US6511508 *||Aug 4, 2000||Jan 28, 2003||Environmental Robots, Inc.||Surgical correction of human eye refractive errors by active composite artificial muscle implants|
|US6549808 *||Oct 19, 2000||Apr 15, 2003||Heinz R. Gisel||Devices and methods for the transcutaneous delivery of ions and the electrical stimulation of tissue and cells at targeted areas in the eye|
|US6647297 *||Apr 17, 2002||Nov 11, 2003||The United States Of America As Represented By The Secretary Of The Navy||Permanent retinal implant device|
|US6718209 *||Feb 5, 2002||Apr 6, 2004||Second Sight Medical Products, Inc.||Retinal prosthesis with remote return electrode|
|US7003355 *||Nov 20, 2002||Feb 21, 2006||Suaning Gregg J||Vision prosthesis for the blind and method for implementing same|
|US20020038134 *||Oct 12, 2001||Mar 28, 2002||Greenberg Robert J.||Package for an implantable medical device|
|US20020095193 *||Jan 16, 2001||Jul 18, 2002||Jerry Ok||Visual prosthesis including enhanced receiving and stimulating portion|
|US20030139784 *||Jul 1, 2002||Jul 24, 2003||Nidek Co., Ltd.||Opthalmic treatment apparatus|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7955389 *||Jun 17, 2008||Jun 7, 2011||National Taiwan University||Artificial sphincter system|
|US8021384||Jan 25, 2007||Sep 20, 2011||Ram Weiss||Extending intrabody capsule|
|US8177778||Oct 29, 2010||May 15, 2012||Avedro, Inc.||System and method for stabilizing corneal tissue after treatment|
|US8202272||Sep 11, 2008||Jun 19, 2012||Avedro, Inc.||Eye therapy system|
|US8348935||Sep 11, 2008||Jan 8, 2013||Avedro, Inc.||System and method for reshaping an eye feature|
|US8398628||Sep 18, 2009||Mar 19, 2013||Avedro, Inc.||Eye therapy system|
|US8409189||Jan 23, 2008||Apr 2, 2013||Avedro, Inc.||System and method for reshaping an eye feature|
|US8460278||Oct 1, 2009||Jun 11, 2013||Avedro, Inc.||Eye therapy system|
|US8469952||Jan 23, 2008||Jun 25, 2013||Avedro, Inc.||System and method for positioning an eye therapy device|
|US20110087138 *||May 29, 2009||Apr 14, 2011||The Regents Of The University Of Colorado, A Body Corporate||Non-invasive device for lowering intraocular pressure|
|WO2008090549A2 *||Jan 21, 2008||Jul 31, 2008||Menachem P Weiss||Extending intrabody capsule|
|WO2010039979A1 *||Oct 1, 2009||Apr 8, 2010||Avedro, Inc.||Eye therapy system|
|International Classification||A61H5/00, A61H1/00, A61N2/12, A61N2/06, A61N1/05, A61N1/36|
|Cooperative Classification||A61N1/36046, A61N2/06, A61N2/12, A61H5/00, A61N1/0543|
|European Classification||A61N2/12, A61H5/00, A61N1/36V|
|Apr 23, 2007||AS||Assignment|
|Feb 15, 2008||AS||Assignment|
Owner name: IMI INTELLIGENT MEDICAL IMPLANTS AG, SWITZERLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OPTOBIONICS CORPORATION;REEL/FRAME:020507/0679
Effective date: 20070921
|Jan 28, 2010||AS||Assignment|
Owner name: OPTOBIONICS CORPORATION, ILLINOIS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHOW, ALAN Y.;MCLEAN, GEORGE Y.;CHOW, VINCENT Y.;AND OTHERS;REEL/FRAME:023867/0034;SIGNING DATES FROM 20040822 TO 20040824
Owner name: OPTOBIONICS CORPORATION,ILLINOIS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHOW, ALAN Y.;MCLEAN, GEORGE Y.;CHOW, VINCENT Y.;AND OTHERS;SIGNING DATES FROM 20040822 TO 20040824;REEL/FRAME:023867/0034
Owner name: IMI INTELLIGENT MEDICAL IMPLANTS AG,SWITZERLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GELFANDBEIN, VLADIMIR;REEL/FRAME:023867/0061
Effective date: 20100120
Owner name: OPTOBIONICS CORPORATION, ILLINOIS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHOW, ALAN Y.;MCLEAN, GEORGE Y.;CHOW, VINCENT Y.;AND OTHERS;SIGNING DATES FROM 20040822 TO 20040824;REEL/FRAME:023867/0034